BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SkinEthic Laboratories Quoted On The Paris Stock Market


10/19/2005 5:08:46 PM

The Nice laboratory SkinEthic can now hear its name called in trading offices throughout the world, having made its Stock Market debut at a minimum price of €6 per share on July 16. The company, founded in 1992 by biologist Martin Rosdy, Ph.D., specializes in the reproduction of human tissue for laboratory testing. The Initial Public Offering is a big success for SkinEthic, which until now has always been self-financed. Profitable by its second year, SkinEthic sales reached €1.63 million by 2003, a figure which the company expects to increase by 14.5% in 2004 and 26.3% in 2005. SkinEthic reconstitutes human tissue models – primarily epidermal and mucosal tissue – using original cell-culture procedures. Cells are grown in a physiologically natural environment, so the tissues obtained behave like human tissues when treated with irritating, pharmacologically active products. With an array of tissue products perfected, the company is now using its patented technology to reconstitute new models, including skin pathologies and 3D liver tissues. SkinEthic enters the free market now to increase its visibility at a strategic time in the testing market. By 2009, the European Union will no longer allow the sale of cosmetics tested on animals. As this decision is predicted to have an influence on pharmaceutical and chemical testing as well, SkinEthic positions itself to provide testing alternatives to animal and human preclinical testing to laboratories worldwide. Labs such as Safepharm, GlaxoSmithKline, Novartis, Pfizer and Johnson & Johnson have already verified the products' effectiveness and reliability. More information : http://www.skinethic.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES